CJC-1295 / Ipamorelin No DAC

CJC-1295 / Ipamorelin No DAC This is a component-based catalog entry for a 10 mg total product sold as CJC-1295 / Ipamorelin No DAC. The vial artwork itself says CJC-1295 / Ipamorelin but does not print “No DAC,” a component ratio, individual strengths, salts, sequence, or analytical identity. A CJC-type no-DAC peptide is intended to signal through the GHRH receptor, while ipamorelin is a GHSR agonist. FDA documents substantial naming ambiguity among “CJC-1295,” “CJC-1295 without DAC,” and related substances, and specifically cautions that pharmacology from the long-acting DAC form cannot be extrapolated to a no-DAC form. No authoritative evidence was identified that validates efficacy or synergy of this exact blend.